EpiEndo Pharmaceuticals

About:

EpiEndo Pharmaceuticals is a clinical biopharmaceutical company focused on novel solutions for chronic airway diseases.

Website: http://www.epiendo.com/

Twitter/X: EpiEndoPharma

Top Investors: European Innovation Council, EASME - EU Executive Agency for SMEs, Brunnur Ventures, Flerie Invest, Kvika Asset Management

Description:

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to inflammatory disorders that focuses on the enhancement of epithelial barrier integrity as a causal pathophysiological factor underlying the etiology of a number of major diseases. Epithelial cells are a key component of the barrier that makes up human skin and lung tissue, as well as the intestinal tract and genitalia. Compromised integrity of this barrier is implicated in the progression and non-resolution of inflammation. EpiEndo is developing a proprietary portfolio of orally available macrolide drug candidates with promise as first-in-class disease-modifying therapeutics, to address the huge global burden of chronic respiratory diseases and other significant unmet medical needs. EpiEndo’s lead drug candidate, EP395, aims to be the first on-market oral, disease modifying, non-antibiotic, barrier strengthening and anti-inflammatory macrolide for COPD and other inflammatory airway diseases.